Skip to content
TrialScanner

NCT03881488

Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies

Phase 1TerminatedCMPXLeadIQVCollaborator

Registry record

Lead sponsor
Compass Therapeutics
Conditions
Locally Advanced Solid Tumor; Metastatic Cancer; Non-small Cell Lung Cancer; Small Cell Lung Cancer; Mesothelioma
Primary completion
May 21, 2025Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03881488 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03881488: Study of CTX-471 as a... | TrialScanner